ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

ClinicalTrials.gov ID: NCT06170788

Public ClinicalTrials.gov record NCT06170788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Study identification

NCT ID
NCT06170788
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
614 participants

Conditions and interventions

Interventions

  • Pembrolizumab Biological
  • Sacituzumab tirumotecan Biological
  • Supportive care measures Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2023
Primary completion
Jan 24, 2028
Completion
May 26, 2030
Last update posted
May 7, 2026

2023 – 2030

United States locations

U.S. sites
15
U.S. states
14
U.S. cities
15
Facility City State ZIP Site status
Mayo Clinic in Arizona - Phoenix ( Site 0147) Phoenix Arizona 85054 Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) Burbank California 91505 Recruiting
Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) Grand Junction Colorado 81501 Recruiting
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) Jacksonville Florida 32224 Recruiting
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) Marietta Georgia 30060 Completed
The University of Louisville, James Graham Brown Cancer Center ( Site 0121) Louisville Kentucky 40202 Recruiting
New England Cancer Specialists ( Site 0143) Westbrook Maine 04092 Recruiting
University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144) Worcester Massachusetts 01655 Completed
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) Minneapolis Minnesota 55407 Recruiting
Mayo Clinic - Rochester ( Site 0148) Rochester Minnesota 55905 Recruiting
Hattiesburg Clinic Hematology/Oncology ( Site 0104) Hattiesburg Mississippi 39401 Recruiting
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) Reno Nevada 89502 Recruiting
University Hospitals Cleveland Medical Center ( Site 0119) Cleveland Ohio 44106 Completed
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117) Corvallis Oregon 97330 Recruiting
Oncology Consultants P.A. ( Site 0129) Houston Texas 77030 Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 203 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06170788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06170788 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →